Our top pick for
Immunomedics, Inc is a biotechnology business based in the US. Immunomedics shares (IMMU) are listed on the NASDAQ and all prices are listed in US Dollars. Immunomedics employs 366 staff and has a trailing 12-month revenue of around USD$20.4 million.
|52-week range||USD$8.8 - USD$87.68|
|50-day moving average||USD$74.5437|
|200-day moving average||USD$44.7741|
|Wall St. target price||USD$75.62|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||USD$-1.631|
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
|Revenue TTM||USD$20.4 million|
|Gross profit TTM||USD$-254,576,000|
|Return on assets TTM||-25.16%|
|Return on equity TTM||-100.04%|
|Market capitalisation||USD$20.3 billion|
TTM: trailing 12 months
There are currently 23.6 million Immunomedics shares held short by investors – that's known as Immunomedics's "short interest". This figure is 11.4% down from 26.6 million last month.
There are a few different ways that this level of interest in shorting Immunomedics shares can be evaluated.
Immunomedics's "short interest ratio" (SIR) is the quantity of Immunomedics shares currently shorted divided by the average quantity of Immunomedics shares traded daily (recently around 8.3 million). Immunomedics's SIR currently stands at 2.85. In other words for every 100,000 Immunomedics shares traded daily on the market, roughly 2850 shares are currently held short.
However Immunomedics's short interest can also be evaluated against the total number of Immunomedics shares, or, against the total number of tradable Immunomedics shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Immunomedics's short interest could be expressed as 0.1% of the outstanding shares (for every 100,000 Immunomedics shares in existence, roughly 100 shares are currently held short) or 0.1143% of the tradable shares (for every 100,000 tradable Immunomedics shares, roughly 114 shares are currently held short).
Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Immunomedics.
Find out more about how you can short Immunomedics stock.
We're not expecting Immunomedics to pay a dividend over the next 12 months.
Immunomedics's shares were split on a 2:1 basis on 24 June 1985. So if you had owned 1 share the day before before the split, the next day you'd have owned 2 shares. This wouldn't directly have changed the overall worth of your Immunomedics shares – just the quantity. However, indirectly, the new 50% lower share price could have impacted the market appetite for Immunomedics shares which in turn could have impacted Immunomedics's share price.
Over the last 12 months, Immunomedics's shares have ranged in value from as little as $8.8 up to $87.68. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Immunomedics's is 2.9018. This would suggest that Immunomedics's shares are significantly more volatile than the average for this exchange and represent a higher risk.
Immunomedics, Inc., a clinical-stage biopharmaceutical company, develops monoclonal antibody-based products for the targeted treatment of cancer. It develops sacituzumab govitecan, an antibody-drug conjugate for the treatment of patients with metastatic triple-negative breast cancer. The company focuses on commercializing sacituzumab govitecan as a third-line therapy for patients with metastatic triple-negative breast cancer in the United States. The company also develops IMMU-140 for treatment of hematologic malignancies; and IMMU-130 to treat Colorectal cancer. Its other product candidates includes epratuzumab, an anti-CD22 antibody; veltuzumab, an anti-CD20 antibody; milatuzumab, an anti-CD74 antibody; and IMMU-114, a HLA-DR antibody. Immunomedics, Inc. has clinical collaboration with AstraZeneca and MedImmune to evaluate Imfinzi, a human monoclonal antibody against PD-L1, with sacituzumab govitecan as a frontline treatment of patients with TNBC and urothelial cancer; collaboration agreement with GBG Forschungs GmbH to develop sacituzumab govitecan for the treatment of breast cancer; and clinical collaboration with F. Hoffman-La Roche Ltd to treat patients with metastatic or inoperable locally advanced TNBC versus atezolizumab plus nab-paclitaxel as standard of care. The company was founded in 1982 and is headquartered in Morris Plains, New Jersey.
Everything we know about the NewRez IPO, plus information on how to buy in.
Everything we know about the Perella Weinberg IPO, plus information on how to buy in.
Everything we know about the Nanobiotix IPO, plus information on how to buy in.
Everything we know about the Diversey IPO, plus information on how to buy in.
Everything we know about the Certara IPO, plus information on how to buy in.
Everything we know about the Arrival IPO, plus information on how to buy in.
Everything we know about the iSpecimen IPO, plus information on how to buy in.
Everything we know about the IDEX Biometrics ASA IPO, plus information on how to buy in.
Steps to owning and managing MYSZ, with 24-hour and historical pricing before you buy.
Steps to owning and managing MG, with 24-hour and historical pricing before you buy.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.